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 22 
Abstract 23 
Fascioliasis is an infectious parasitic disease distributed globally and caused by the liver 24 
flukes Fasciola hepatica or F. gigantica. This neglected tropical disease affects both 25 
animals and humans and it represents a latent public health problem due to the significant 26 
economic losses related to animal husbandry. For decades, Triclabendazole has been the 27 
unique anti-Fasciola drug that can effectively treat this disease. However, triclabendazole 28 
resistance in Fascioliasis has been more recently reported around the world, and thus the 29 
discovery of novel drugs is an urgent need. The aim of this study was to investigate the 30 
fasciocidal properties of 400 compounds contained in the Pathogen Box.  The first stage of 31 
the screening was carried out by measuring the fasciocidal activity on metacercariae at a 32 
concentration of 33 μM of each compound (standard dose). Subsequently the 50% 33 
inhibitory concentration (IC50) values of the most active compounds (n=33) were assayed 34 
on metacercariae and resulted in 13 compounds with IC50 < 10 μM. The second stage 35 
queried these compounds at 33 μM on adult flukes where seven showed high mortality 36 
rates > 50%. Four hit compounds were selected based on predicted nontoxic properties and 37 
IC50 values obtained on adult worms resulted < 10 μM thus representing the best 38 
fasciocidal compounds tested here. Cytotoxicity assay on four types of cell lines 39 
demonstrated that three compounds are nontoxic at its most active concentration. In 40 
conclusion, three hit compounds identified in this proof-of-concept study are potential 41 
candidates in the discovery of new fasciocidal drugs. Further studies are warranted.  42 
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INTRODUCTION 43 
Fasciola hepatica is the etiological agent of fascioliasis, the most widespread trematodiasis 44 
that affects both humans and herbivorous mammals such as sheep, cattle, goats and other 45 
species (1, 2). In humans, fascioliasis can be acquired by the consumption of contaminated 46 
vegetables. Up to 17 million people in 51 countries are estimated to be infected with F. 47 
hepatica worldwide and more than 91 million are at risk of infection by this parasite (3, 4). 48 
Among all continents, the Andean Region of South America is the most affected by 49 
Fasciola where prevalence rates above 10% have been documented (5-8) and national 50 
treatment programs are being scaled up.  51 
Triclabendazole (TCBZ) is the most single effective fasciocidal drug, with activity against 52 
both the infective larvae (Metacercaria) and adult worms, and an efficacy that exceeds 90% 53 
in humans after a single oral dose (9, 10). Nonetheless, after decades of successful efficacy, 54 
TCBZ resistance has developed in both animals and humans (11). Cases of TCBZ-resistant 55 
Fasciola in both animals and humans have been reported in Australia, Europe and Latin 56 
America (12-18). The development of TCBZ resistance represents an important public 57 
health concern throughout the world that mainly affects animal husbandry and leads to 58 
enormous economic losses (19). As a consequence, the discovery of novel effective drugs 59 
and vaccines against Fasciola is an urgent need for the global control of fascioliasis. 60 
Repurposing of praziquantel (PZQ) as anti-Fasciola drug failed whereas oxfebendazole 61 
showed to be an effective drug in animals (20, 21). Currently, there is no other fasciocidal 62 
drug in clinical practice for humans, and thus TCBZ remains the unique treatment against 63 
this infectious disease. 64 
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Open-access drug discovery provides a substantial resource in the research of those 65 
diseases that affect primarily people living in low-resources locations. The Medicines for 66 
Malaria Venture (MMV) foundation assembled a set of compounds, called “Malaria Box”, 67 
which has been tested against various infectious agents including Cryptosporidium parvum 68 
(22), Plasmodium falciparum (23, 24) Schistosoma mansoni (25, 26), Toxoplasma gondii 69 
(27), and mycobacteria (28, 29). Later, a new set of chemical entities was assembled and 70 
named the Pathogen Box collection. It contains 400 drug-like compounds that have showed 71 
inhibitory activity on various infectious diseases such as haemonchosis, toxoplasmosis, 72 
tuberculosis, neosporosis, malaria, sleeping sickness, Chagas, leishmaniasis and 73 
trypanosomiasis (30-36). The Pathogen Box has been tested also in fungal diseases caused 74 
by Cryptococcus neoformans and Candida albicans (37-39). The aim of this study was to 75 
identify the fasciocidal activity of 400 compounds contained in the Pathogen Box by in 76 
vitro testing. 77 
 78 
MATERIALS AND METHODS 79 
Study design. The study was conducted in three stages: (i) bioassays on metacercariae; (ii) 80 
bioassays on adult worms; and (iii) cytotoxicity on cell (Figure 1). The best ffasciocidal 81 
compounds were selected in each stage to be tested in the next phase based on in vitro 82 
biological activity. To complement our knowledge on the active compounds obtained by 83 
the experimental assays, computational resources were consulted to describe the chemical 84 
properties as well as the in silico toxicology features and biological targets from these 85 
active compounds.   86 
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 87 
Drugs and Media 88 
The Pathogen Box was provided by the MMV agency (Geneva, Switzerland) and 89 
manufactured by Evotec (USA). The 400 drug-like molecules were supplied in 96-well 90 
plates as stock solutions of 10 mM dissolved in dimethyl sulfoxide (DMSO). Full data of 91 
The Pathogen Box compounds is available at https://www.pathogenbox.org (40). TCBZ 92 
was purchased from Sigma-Aldrich (Buchs, Switzerland). All of the compounds of The 93 
Pathogen Box were dissolved in DMSO (Sigma-Aldrich, Irvine, UK) for drug stock 94 
solutions of 200 μM. Additional vials of MMV063404, MMV003270, MMV085210, 95 
MMV676380, MMV687730, MMV687251, MMV1030799, MMV690102, MMV1029203, 96 
MMV676053, MMV688179, MMV023969 and MMV688921 were manufactured by 97 
Evotec (France). RPMI 1640 culture medium (Sigma- Aldrich, St. Louis, US) was used for 98 
both stages, metacercariae and adult worm; supplemented with penicillin (100 U/ml) and 99 
streptomycin (100 μg/ml) (Sigma-Aldrich, St. Louis, US).  100 
Parasites 101 
Metacercariae of F. hepatica were obtained following the protocol described by Ortiz et al. 102 
(16), at the Immunology and Research Laboratory of the Faculty of Veterinary Sciences of 103 
the Universidad Nacional de Cajamarca in Peru. Eggs of F. hepatica were collected 104 
directly from the gallbladder of sheep slaughtered in a popular abattoir in the city of 105 
Cajamarca (TCBZ-resistant endemic area for fascioliasis). Miracidia were from Fasciola 106 
eggs after incubation for 15 days at 25°C. Afterwards, they were used to infect Lymnaea sp. 107 
snails (5-6 mm) in a proportion of two miracidia per snail. The infected snails were kept in 108 
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plastic containers for 45 to 60 days at room temperature. After this time, the snails were 109 
stimulated by direct solar exposure and water at 4-8°C to produce metacercaria. 110 
Approximately 20,000 metacercariae were obtained for this study and stored in cryovials 111 
on distilled water at 4-8°C. Adult worms were collected from bile ducts of infected cattle 112 
from a slaughterhouse in Lima, Peru; and maintained at 37°C until usage (within 2h). 113 
Before its incubation, three washes with phosphate-buffered saline (PBS) (HiMedia, India) 114 
and one additional with supplemented RPMI were performed to remove host debris. All the 115 
incubations, for both metacercariae and adults, were carried out at 37°C with 5% CO2. 116 
In vitro screening on metacercariae  117 
The 400 compounds were initially tested at 33 μM on F. hepatica metacercariae. Drug 118 
stock solutions were diluted in 96-well plates (BD Falcon, US) with RPMI 1640 119 
supplemented with antibiotic up to a final volume of 180 μL. In all in vitro assays, positive 120 
and negative controls were run in parallel for each assay batch. A range between seven and 121 
ten metacercariae were added to each well, previously analyzed microscopically to confirm 122 
its viability (microscopic features intact). The metacercariae viability considered some 123 
physical properties of the parasite determined by microscopy as described previously (41, 124 
42). The MCs viability was surveyed as a function of both damage in membrane and fluke  125 
colour (translucence). Therefore, a low viability corresponded to big damage and high 126 
translucency. The viability scale was scored as follows: +++, total damage (dead parasite, 127 
shattered membrane and mostly translucent); ++, partial damage (partial membrane damage 128 
and highly translucent); +, mild damage (partial membrane damage, poorly translucent) and 129 
no damage (intact membrane, dark metacercariae, lack of translucency). 130 
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Positive-control wells contained TCBZ 10 μM whereas F. hepatica metacercariae 131 
incubated in the presence of the highest concentration of DMSO served as negative control. 132 
Each test was performed in triplicate. Culture plates were incubated at 37°C in a humidified 133 
5% CO2 atmosphere for 72 h. First, metacercariae were evaluated by inverted microscopy 134 
(PhotoZoom, Cambridge Instruments) at magnification 10X and 20X at 24, 48 and 72 h 135 
post drug exposure to determine its viability. Only the compounds that caused,  on average, 136 
at least 25% of metacercariae mortality at 72 hours were considered for IC50 (50% 137 
inhibitory concentration) determination. Experiments were run in sets of triplicates. The 138 
mean mortality percent of the study compounds were compared to that of DMSO. A 139 
standard deviation (SD) was also estimated. 140 
In the second part, we determined the IC50 of the selected compounds chosen in the 141 
previous bioassay. Drugs were tested at concentrations of 2.1, 4.2, 8.4 and 33 μM using 142 
supplemented culture medium. The incubation was done under the conditions described 143 
above, by triplicate and considering TCBZ and DMSO as controls. Anti-parasite activity 144 
was evaluated at 24, 48 and 72 h post exposure, using the above-mentioned metacercariae 145 
viability scale. Viability (mean % of viable parasites) at 72h was considered for the 146 
estimation of IC50. IC50 values of test compounds were determined by linear regression 147 
analysis using CompuSyn software (Version 3.0.1, 2007; ComboSyn Inc., USA). The linear 148 
correlation coefficient (r) was obtained.    149 
Assessment of anti-Fasciola activity in vitro on adult worms  150 
Those compounds that showed activity IC50 < 10 μM on metacercaria were subsequently 151 
tested in adult stage of F. hepatica. In all in vitro assays, positive and negative controls 152 
were run in parallel for each assay batch. First, the selected compounds were tested at 33 153 
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μM by triplicate, using drug stock solutions diluted in supplemented RPMI on 6-well plate 154 
up to a final volume of 4 ml. Adult worms were thoroughly washed with PBS to remove 155 
host debris and then three worms were placed in each well. The incubation was done under 156 
the same conditions as those applied in bioassays with metacercariae. Positive control 157 
consisted of 50 μM TCBZ and the negative control was DMSO at the highest 158 
concentration. The viability of adult flukes was scored after 24 and 48 h using a motility 159 
criterion previously described (43) and also color and rigidity criteria previously applied by 160 
our team (data not published). Motility was assessed only in adults and not in MC because 161 
this latter has no movements. Rigidity was a parameter used to confirm the damage caused 162 
by the drug once the incubation time finished. In general, low motility level corresponded 163 
to transparent and rigid worms. Those changes were attributed to the damage caused by a 164 
drug. The viability scale was determined as follows: (i) worm motility: 3, normal 165 
movements; 2, reduced movements; 1, very weak movements and 0, absence of movements 166 
(i.e. death of worm); (ii) worm color: +++, dark red; ++, pink; +, slightly transparent and -, 167 
totally transparent; and (iii) worm rigidity: -, no rigidity; +, rigidity and ++, cell break when 168 
touched. Assessments at 72h post drug exposure were not done because death of worms 169 
always occurred < 48h. Experiments were run in sets of triplicates. The mean mortality 170 
percent and SD of the study compounds were estimated. The selected compounds were 171 
those that caused an average mortality > 50% in adult parasites. Then IC50 assays were 172 
conducted by testing the selected compounds at five different concentrations 0.31, 0.93, 173 
2.78, 8.33 and 25.0 μg/ml. DMSO and TBZ were used as negative and positive controls, 174 
respectively.  Parasite viability at 24 h were estimated based on survival in DMSO. The 175 
IC50s and 95% CI were estimated using GraphPad Prism 7.0 software using a variable 176 
slope of the sigmoidal curve from normalized percent activity values and log10-177 
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transformed concentrations. Top and bottom values were constrained to 100 and 0, 178 
respectively. The fasciocidal activity was determined by considering the adult viability 179 
scale described before.         180 
Computational analysis. 181 
Evaluation of biological targets of small compounds. To learn about biological targets, 182 
those compounds that showed promising anti-fasciola activity in the adult stage as well as 183 
TCBZ were entered in the ChEMBL database (https://www.ebi.ac.uk/chembl/) (44). First, 184 
the SMILES (Simplified Molecular-Input Line-Entry System) of each selected compound 185 
were obtained from the supplementary material provided by the MMV (also available at 186 
www.mmv.org).  Then the SMILES were entered in ChEMBL and known targets of each 187 
compound were retrieved. ChEMBL compares the query compound to a large database of 188 
compounds and their targets available from multiple sources including the projects funded 189 
by MMV (45). The target name, organism and protein target classification were collected. 190 
In silico cytotoxicity prediction. Lazar (lazy structure–activity relationships), a modular 191 
framework for predictive toxicology, was consulted to predict the toxic effects of the 192 
selected compounds that showed activity on metacercariae (46-48). Lazar was accessed 193 
through https://lazar.in-silico.de/predict and SMILES of each compound were entered. 194 
Relevant data including carcinogenicity in rodents, mutagenicity in Salmonella typhi and 195 
acute toxicity on Fathead minnow, Blood Brain Barrier Penetration and the maximum 196 
recommended daily dose in humans were predicted.   197 
Cell Growth Inhibition Bioassay.  198 
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Cytotoxicity of the compounds was evaluated in tumor and non-tumor cell lines using the 199 
sulforhodamine B (SRB) assay method (49, 50). Cell lines tested include BALB/3T3 (Non-200 
tumorogenic, BALB/c mouse embryo cells), H460 (human lung large cell carcinoma), 201 
DU145 (human prostate carcinoma) and HT-29 (human colon adenocarcinoma).  202 
To determine the cytotoxicity of the compounds, cells were plated into 96-well tissue 203 
culture plates and in their corresponding growth medium Dulbecco’s Modified Eagle 204 
Medium (DMEM) at approximately 10% confluency (BALB/3T3 at 3,500 cells/well, H460 205 
at 1,500 cells/well, DU145 at 3,500 cells/well and HT-29 at 3,000 cells/well) and incubated 206 
at 37˚C in a 5% CO2 and 95% air humidified atmosphere for 24 h to allow cells to attach. A 207 
plate containing each of these cells was fixed in situ with trichloroacetic acid (TCA) in 208 
order to obtain the cell values at zero time before adding the compounds. The rest of the 209 
plates containing the different cell lines received serial dilutions of the compound to be 210 
tested at the following final concentrations: 4, 1, 0.25 and 0.0625 μg/mL. The plates were 211 
then incubated at 37˚C in a 5% CO2 and 95 % air humidified atmosphere for 48 h. The 212 
assay was terminated by the addition of cold TCA. TCA treated plates were incubated at 213 
4˚C for 1 hour and then washed five times with tap water to remove TCA and air dried. 214 
Background optical densities were measured in wells incubated with growth medium 215 
without cells. TCA-fixed cells were stained for 20 minutes with 0.4% (w/v) SRB dissolved 216 
in 1% acetic acid. At the end of the staining period unbound dye was removed by washing 217 
four times with 1% acetic acid. After air drying the plates, bound dye was solubilized with 218 
10 mM Tris base (pH 10.5) and the absorbance read on an automated plate reader at a 219 
wavelength of 550 nm. The GI50 value was defined as the concentration of test sample 220 
resulting in a 50% reduction of absorbance as compared with untreated controls that 221 
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received a serial dilution of the solvent in which the test samples were dissolved and was 222 
determined by linear regression analysis. The optical density values obtained were used to 223 
determine the cell growth and cytotoxicity from each compound. 224 
Ethics. This study was approved by the Animal Ethics Committee of the Universidad 225 
Peruana  Cayetano Heredia (Approval ID Code 41-07-16).  226 
RESULTS 227 
In vitro activity of The Pathogen Box determined on F. hepatica metacercariae  228 
In the first stage of the study, the 400 compounds contained in the Pathogen Box were in 229 
vitro screened against F. hepatica metacercaria. A total of 33 compounds showed mean 230 
mortality rates above 25%  at 33 ?M but all these resulted being less active than TCBZ 231 
(mortality rate of 90%) as shown on Table 1. Fasciocidal activity of these 33 compounds 232 
was then assessed by determining the IC50 values (Table 1). As a result, 13 compounds 233 
showed potent inhibitory activities with IC50 values between 0.31 μM and 8.23 μM and 234 
were then assayed in adult worms although its low r values (Table 1).  235 
In vitro activity of selected compounds on F. hepatica adult worms and in silico toxicology 236 
prediction. 237 
The 13 selected compounds listed on Table 2 were assayed at 33 μM in adult worms. Seven 238 
compounds produced moderate or high mean mortality rates (> 50%)  (Table 2). These 239 
were MMV003270, MMV676380, MMV690102, MMV1029203, MMV063404, 240 
MMV1030799, and MMV688921. Six compounds showed low mortality rates (<50%) and 241 
for that reason these were not considered in the next assays. Before to proceed with the IC50 242 
assay, in silico safety profiles of the seven selected compounds were predicted by lazar 243 
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program (Table 1). Whereas MMV003270 and MMV676380 were predicted non-244 
carcinogenic and non-tumorigenic compounds, MMV690102 was deemed non-245 
carcinogenic and tumorigenic (Table 1). MMV1029203, MMV063404, MMV1030799, and 246 
MMV688921 were predicted carcinogenic and tumorigenic substances. Thus, the three 247 
deemed non-carcinogenic compounds as well as MMV1029203, a predicted carcinogenic 248 
substance that had the highest mean mortality rate (78%), were tested in adult worms. Such 249 
four compounds constitute our hit compounds.  250 
To determine which of the four hit compounds were most potent at inhibiting the growth of 251 
F. hepatica adult worms, the IC50 values were determined. The hit compounds had IC50 252 
values < 10 μM in adult worms (Table 3, Fig. S1, Table S1).  These four hit compounds 253 
were tested in the cytotoxicity study on cell cultures.  254 
In vitro cytotoxicity on cell lines. 255 
Cytotoxicity of the four hit compounds against cell lines was evaluated in culture (Table 3).  256 
The GI50 values ranged from 0.95 and >23.73 μM across the four types of cell lines assayed 257 
(Table 3). MMV003270, MMV676380, MMV1029203 and TCBZ presented GI50 values 258 
above its IC50 values thus meaning that these compounds are not toxic at their active 259 
concentrations. In one of the four cell lines, MMV690102 had a GI50 value below its IC50 260 
value thus suggesting that it may cause a level of toxicity in certain cell types at its active 261 
concentration (Table 3).  262 
Computational recognition of targets. 263 
As a result of the search in the ChEMBL database, a total of 27 targets were recognized for 264 
TCBZ whereas MMV003270 resulted to have 19 known target, most of them in humans 265 
 on January 3, 2019 by guest
http://aac.asm.org/
Downloaded from 
13 
 
(Table 4). MMV003270 and TCBZ have common human targets that comprise Nuclear 266 
factor erythroid 2-related factor 2, Microtubule-associated protein tau and TAR DNA-267 
binding protein 43. According to the data deposited in ChEMBL, MMV003270 targets a 268 
number of cytochrome p450 of family 1, 2 and 3. MMV676380 and MMV023969 have 269 
identical cell targets that include human glucose transporter and hexose transporter of 270 
Plasmodium falciparum and Leishmania mexicana (Table 4). Targets for MMV1029203 271 
and MMV676053 also resulted to have known targets including human ferrochelatase and 272 
Inosine-5'-monophosphate dehydrogenase of Cryptosporidium parvum, respectively. The 273 
remaining eight compounds had no known targets according to the ChEMBL database 274 
(Table 4). 275 
 276 
DISCUSSION 277 
In the present study, the Pathogen Box was queried to identify compounds with in vitro 278 
anti-Fasciola activity against both metacercariae and adult worms (Figure 1). We found 13 279 
compounds with potent inhibitory activity on metacercariae (IC50 < 10 μM), meaning that 280 
3% of the substances within the Pathogen Box are effective against the infective form of F. 281 
hepatica. Two out of the 13 compounds (MMV687730 and MMV687251) had the most 282 
potent activity against metacercariae with IC50 values below 1 ?M but showed mild effects 283 
on adult worms (Tables 1 and 2). Since we were interested in identifying hit compounds 284 
that were active on larvae and adult stages, these two compounds were not further studied 285 
(Table 2). When assayed on adult worms, seven promising compounds showed mortality 286 
rates above 50% (Table 2). As a criterion for hit prioritization during the screening on adult 287 
worms, we prepared a list of hit compounds that mostly excluded the predicted 288 
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carcinogenic/tumorigenic compounds (Table 3). Thus, three (MMV676380, MMV003270 289 
and MMV690102) of the seven most promising candidates were included in the list of hit 290 
compounds since they were predicted noncarcinogenic agents (Table 1). One additional 291 
compound (MMV1029203) that was predicted as a carcinogenic compound was also 292 
included due to its very high effect on adult worms. According to our results, the four hit 293 
compounds resulted potent inhibitory molecules both on MC and adult stages (Table 3). 294 
The cytotoxicity assay revealed that three hit compounds (MMV676380, MMV003270 and 295 
MMV1029203) were non-toxic agents at its most active concentrations when assayed on 296 
cell lines (Table 3). In contrast, MMV690102 may cause cell cytotoxicity at its most active 297 
concentration meaning that it is not a primary candidate for drug development (Table 3). 298 
Our results are consistent with previous cytotoxicity assays on HepG2, HL60 and MRC5 as 299 
shown on Table 3 (data provided by the MMV as part of the supporting information for the 300 
Open Access Malaria Box).  301 
Repurposing of hits, using the Pathogen Box, against F. hepatica is highly relevant since 302 
TCBZ is the only existing effective drug for which resistance is known (51-53). Previous 303 
works tried to repurpose albendazole, nitroxynil and closantel as candidate fasciocidal 304 
drugs but treatment failed (54, 55). In the present study, four out of 400 compounds 305 
contained in The Pathogen Box showed potent inhibitory activity against the infective form 306 
of F. hepatica as well as its adult form (Table 3). Such finding represents a relevant 307 
contribution in the identification of dual drug candidates that are able to act against the 308 
initial stages of the infective larvae (metacercaria) and adult forms of liver flukes, similar to 309 
TCBZ. Additionally, other 13- compounds showed biological activity at < 20 ?M against 310 
metacercaria (Table 1). Since MC represents the initial infective form of parasites, it should 311 
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be primarily controlled through potent compounds such as those identified here (Table 1). 312 
Future exploration of The Pathogen Box in newly juvenile metacercaria is desirable given 313 
that some compounds may have not penetrated the cyst wall of larvae. By testing 314 
compounds on juvenile worms, some additional molecules might be recognized that are 315 
active in adult worms.  316 
 317 
The four hit compounds identified in this study have been previously characterized against 318 
Plasmodium falciparum, Ancylostoma ceylanicum, Trypanosoma cruzi and Leishmania 319 
donovani (data provided by the MMV as part of the supporting information for the Open 320 
Access Malaria Box).  Therefore, a common mechanism of action or target is plausible 321 
among the hit compounds across such pathogens. For instance, MMV676380 has 322 
previously shown to have a lethal effect on P. falciparum and here was found to be a potent 323 
inhibitory compound against F. hepatica (36, 56). Known targets of MMV676380 are the 324 
glucose and hexoses transporters suggesting that such mechanism may be affected in both 325 
parasites in presence of such compound (Table 4). In the other hand, MMV003270 326 
(Zoxazolamine), that is also active against A. ceylanicum, resulted to have 19 targets 327 
including three human proteins that are also targeted by TCBZ (Table 4). Two of these 328 
proteins are transcription regulators (Nuclear factor erythroid 2-related factor 2 and TAR 329 
DNA-binding protein 43) whose disruption may affect the gene expression. Such finding is 330 
in accordance with a hypothetical mechanism of action of TCBZ that involves a direct 331 
effect of the drug on protein synthesis (11, 57). Similarly, the microtubule-associated 332 
protein tau is a known target both of TCBZ and MMV003270. TCBZ is a benzimidazole-333 
derivative that disrupts the assembly of microtubules in helminths by binding to tubulin 334 
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molecules (58). Our results suggest that MMV003270 also affects the microtubules 335 
formation mechanism. Common targets of TCBZ and MMV003270 may be partially 336 
explained by the similar scaffold structures. MMV1029203, one of the four hit compounds, 337 
targets a human ferrochelatase that is a mitochondrial factor involved in protoheme 338 
biosynthesis. This latter is a vital process that exists also in F. hepatica and whose 339 
disruption may be lethal. Some known targets of the hit compounds here identified 340 
correspond to human proteins which suggests that a level of toxicity may exist in humans. 341 
However according to our results with cell lines, the compound concentrations needed to 342 
kill F. hepatica (IC50) are considerably less than that to cause cell death (GI50) which means 343 
that these are nontoxic (Table 3), except for MMV690102. Although no F. hepatica target 344 
is recognized for our hit compounds, the demonstration of inhibitory activity of such 345 
chemical agents both in metacercariae and adult forms suggests that common targets may 346 
exist in both liver fluke stages. The identification of drug targets becomes an important step 347 
that drive the discovery of novel antiparasitic agents administered by various ways (34). 348 
For that reason, further studies to identify potential F. hepatica targets of hit compounds are 349 
desirable. Such a study should consider the recognition of human homologs in F. hepatica 350 
according to our results (Table 4). 351 
Our study has some limitations. First, TCBZ metabolites (TCBZ-sulfoxide and TCBZ-352 
sulfone) that are quickly released in vivo were not included in this pilot study. However 353 
given that TCBZ has a moderate in vivo and in vitro fasciocidal effects it is suitable as 354 
positive control in bioassays (59, 60). A second limitation is that alive F. hepatica worms 355 
were collected from a local abattoir where some animals may have been infected by various 356 
other pathogens or may have been treated with TCBZ. To guarantee the best quality of 357 
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adult worms for bioassays, we performed a quality control on adult fasciolas before using 358 
these in the experiments. Thus, only worms that presented intense brown or red color and 359 
that have active motility were selected. All the remaining were discarded. A third limitation 360 
is the low number of parasites used for the assays, that did not allow performing formal 361 
statistical comparisons of activity between TCBZ and test drugs.  Obtaining MC and adults 362 
was a challenging task since both MC and adult worms were collected from natural 363 
reservoirs. Therefore we had limited access to parasites for bioassays. However, our 364 
exploratory study aimed to identify fasciocidal compounds, we found that negative controls 365 
were enough for such purposes.   366 
In conclusion, we identified three promising non-cytotoxic drug-like compounds, 367 
MMV003270, MMV676380 and MMV1029203, that showed a potent biological activity 368 
against F. hepatica metacercaria and adult worms. Such compounds represent new lead 369 
candidates to potentially become future anti-F. hepatica drugs. By acting both on infective 370 
form and adult worms, such agents may provide an appropriate treatment against 371 
fascioliasis. 372 
 373 
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